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ORIGINAL ARTICLE
Evidence for a differential role of HPA-axis function,
inﬂammation and metabolic syndrome in melancholic versus
atypical depression
F Lamers1, N Vogelzangs2, KR Merikangas1, P de Jonge3, ATF Beekman2 and BWJH Penninx2,3,4
The hypothalamic–pituitary–adrenal (HPA) axis and the inﬂammatory response system have been suggested as pathophysiological
mechanisms implicated in the etiology of major depressive disorder (MDD). Although meta-analyses do conﬁrm associations
between depression and these biological systems, effect sizes vary greatly among individual studies. A potentially important factor
explaining variability is heterogeneity of MDD. Aim of this study was to evaluate the association between depressive subtypes
(based on latent class analysis) and biological measures. Data from 776 persons from the Netherlands Study of Depression and
Anxiety, including 111 chronic depressed persons with melancholic depression, 122 with atypical depression and 543 controls were
analyzed. Inﬂammatory markers (C-reactive protein, interleukin-6, tumor necrosis factor-a), metabolic syndrome components, body
mass index (BMI), saliva cortisol awakening curves (area under the curve with respect to the ground (AUCg) and with respect to the
increase (AUCi)), and diurnal cortisol slope were compared among groups. Persons with melancholic depression had a higher AUCg
and higher diurnal slope compared with persons with atypical depression and with controls. Persons with atypical depression had
signiﬁcantly higher levels of inﬂammatory markers, BMI, waist circumference and triglycerides, and lower high-density lipid
cholesterol than persons with melancholic depression and controls. This study conﬁrms that chronic forms of the two major
subtypes of depression are associated with different biological correlates with inﬂammatory and metabolic dysregulation in atypical
depression and HPA-axis hyperactivity in melancholic depression. The data provide further evidence that chronic forms of
depressive subtypes differ not only in their symptom presentation, but also in their biological correlates. These ﬁndings have
important implications for future research on pathophysiological pathways of depression and treatment.
Molecular Psychiatry (2013) 18, 692–699; doi:10.1038/mp.2012.144; published online 23 October 2012
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INTRODUCTION
Three often-studied pathophysiological systems that have a role in
the etiology of major depressive disorder (MDD) are the
hypothalamic–pituitary–adrenal (HPA) axis, the inﬂammatory
response system and metabolic abnormalities. HPA-axis hyper-
activity has been demonstrated in depressed persons compared
with controls, and has been further implicated as a potential
mechanism through which depression increases the risk of
cardiovascular disease and other somatic diseases.1 Alterations
in the immune response system have been reported as well, with
depressed persons having higher serum levels of pro-
inﬂammatory cytokines such as C-reactive protein (CRP),
interleukin (IL)-6 and tumor necrosis factor (TNF)-a compared
with healthy individuals.2–4 Related to this, more metabolic
abnormalities such as obesity and adverse lipoprotein patterns
are also associated with MDD,5–7 and several studies have shown
an association between depression and metabolic syndrome.8,9
Although meta-analyses have conﬁrmed signiﬁcant associations
between depression and HPA-axis measures (cortisol, adrenocor-
ticotropic hormone) and inﬂammation (CRP, IL-6, TNF-a), there is
substantial variability in the effect sizes across studies.1,2,10 Such
variability could be attributable to sampling (for example, clinical
sample versus community), composition of the sample (for
example, age and ethnic composition) or to methodological
differences in measures of depression and biological correlates.
For example, previous studies have indicated that chronic
depression, speciﬁcally dysthymia, may differ from non-chronic
depression in levels of inﬂammatory markers.11 However,
variability could also be associated with the heterogeneity of
the MDD diagnosis, particularly to differences in biological
systems among those with different depressive subtypes. We
hypothesize that the heterogeneity of MDD signiﬁcantly
contributes to this variability.
Some evidence in support of this hypothesis suggests that
depressive subtypes contribute to variability in associations with
biological measures. Subtypes represent more homogeneous
groups of cases, and may potentially have different underlying
pathophysiological processes. For instance, the association
between melancholic depression and the HPA-axis hyperactivity
has been replicated in some studies, whereas persons with
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atypical depression have been found to have a lower cortisol
values than persons without atypical depression.1,12,13 Atypical
features were recently linked to decreased IL-4 and increased IL-2
compared with persons without atypical features in one study,14
while another study reported decreased IL-2 in atypical depression
compared with controls.11 Another study found no differences in
CRP, IL-6 and TNF-a between melancholic and atypical depression,
and a higher CRP in atypical depression compared with controls in
multivariable analyses.15 Findings on inﬂammatory markers
among those with melancholic depression have been
contradictory; whereas one study reported higher IL-1b among
melancholics,16 others found lower IL-1b compared with non-
melancholics.17 Based on meta-analytic work, Howren et al.3
concluded that body mass index (BMI) may interact with CRP and
IL-6 to yield a potential tridirectional relationship between
adiposity, inﬂammation and depression. The high BMI levels of
those with atypical depression18,19 may indicate a differential
association between atypical depression with inﬂammation
compared with melancholic depression, as was also postulated
by Gold and Chrousos.12
In the past, substantial research has been devoted to the
identiﬁcation of subtypes of depression20 based on clinical
correlates, treatment response or observed symptom proﬁles.
Opposed to following these paths, a more novel way of identifying
subtypes has become available in the form of data-driven
techniques, which result in more empirically based subtypes.
Using such techniques, we previously observed subtypes closely,
but not exactly, matching the DSM-IV (Diagnostic and Statistical
Manual of Mental Disorders, 4th Edition) atypical and melancholic
depression.18,21 In line with a previous ﬁnding that metabolic
syndrome was associated with neurovegetative symptoms of
depression,22 we observed differences between atypical and
melancholic depression, including higher rates of metabolic
syndrome.18 If more homogeneous subtypes have different
biological proﬁles, this may help bring us closer to underlying
etiologies, and can help direct future etiological research and
treatment development. Although several researchers have
addressed differences in biological measures across depressive
subtypes, to our knowledge, no previous studies have rigorously
evaluated different biological systems among depressive subtypes
and controls simultaneously.
Our previous empirical work on the Netherlands Study of
Depression and Anxiety (NESDA) sample distinguished two severe
depressive subtypes that differed in depressive symptom proﬁle—
one resembling melancholic and one resembling atypical depres-
sion.18,21 The aim of the current study was to compare different
pathophysiological indicators of HPA-axis function, the
inﬂammatory response system and metabolic syndrome across
these two subtypes of MDD and healthy controls. We expect that
melancholic depression will show more pronounced HPA-axis
hyperactivity, whereas atypical depression will, in this respect,
not differ from controls. Further, we expect that atypical
depression will show a proﬁle of immune activation and
metabolic abnormalities compared with melancholic depression,
whereas melancholic depression and controls will not differ from
each other in this aspect.
MATERIALS AND METHODS
Sample
Data from NESDA were used.23 NESDA is a longitudinal naturalistic cohort
study, consisting of 2981 persons (18–65 yrs), including those with lifetime
or current anxiety and/or depressive disorders (n¼ 2329; 78%) and healthy
controls (n¼ 652; 22%).23 Participants were recruited from the community
(n¼ 564; 19%), primary care (n¼ 1610; 54%) and specialized mental health
care (n¼ 807; 27%) from September 2004 through February 2007 at three
study sites (Amsterdam, Groningen and Leiden). Approval of the study
protocol was granted by the Ethical Review Boards of all the participating
centers and all the participants gave written informed consent. Exclusion
criteria were (1) a primary clinical diagnosis of psychotic disorder,
obsessive compulsive disorder, bipolar disorder or severe addiction
disorder and (2) not being ﬂuent in Dutch. At baseline, participants were
invited for a 4-h interview at one of the three study sites. Information was
collected on psychopathology, demographic characteristics, physical and
psychosocial functioning. It further included a blood draw, medical
assessment, computer tasks, two self-administered questionnaires and
salivary cortisol assessment. For the current study, we included 776
persons, including 233 persons with a current diagnosis of MDD whose
subtype has been established (see below for details), and 543 controls
without lifetime depressive or anxiety disorders.
Depressive subtypes
MDD was diagnosed with the Composite International Diagnostic Inter-
view (CIDI) lifetime version 2.1,24 which was conducted by trained clinical
research staff. For the current study, we used two depressive subtypes, a
Severe Melancholic (n¼ 111) and a Severe Atypical (n¼ 122) subtype,
which were previously identiﬁed based on a latent transition analysis (LTA)
of patients with persistent chronic depression. Chronic depression was
deﬁned as having a current (12-month) diagnosis of MDD at both the
baseline and at the 2-year follow-up measurement.
A detailed description of the LTA analyses and subtypes can be found
elsewhere.21 In short, 10 depressive symptoms from the CIDI were used as
indicator variables to identify depression subtypes at each measurement.
In the ﬁrst step of these data-driven analyses, persons with similar
symptom-endorsement patterns were clustered in classes. In a second
step, after identifying the best-ﬁtting models for each time point,
transitions over time were modeled in a longitudinal analysis. The
analyses revealed three subtypes of depression that were labeled by the
researchers based on their observed symptom patterns: a Severe
Melancholic/Typical subtype (average prevalence across time points:
27.2%) characterized by decreased appetite and weight loss, a Severe
Atypical subtype (32.2%) characterized by overeating and weight gain, and
a Moderate subtype (40.5%) that was characterized by lower symptom
probabilities and overall lower severity. Transition analyses showed that
76% of the sample endorsed the same subtype at both measurements,
indicating that this group had a relatively stable depressive subtype. It
should be noted that our labels for subtypes do not refer to the DSM-
classiﬁers. However, inclusion of the symptoms of mood reactivity and
interpersonal sensitivity in the current deﬁnition atypical depression has
been debated,25–28 and this was underlined in our latent class analysis
(LCA) analysis showing that these two symptoms did not discriminate
subtypes.18 Also, other LCA studies have found similar symptom patterns
with appetite and weight being the most discriminating symptoms,
showing robustness of the identiﬁed subtypes.19,29 Because our labels
were used to describe the classes in previous work, we use the same labels
here as well for consistency, but it is important to point out that our LCA-
based subtypes of melancholic and atypical depression are, thus, not
literally resembling DSM-classiﬁcations but are based on LCA-driven
analyses. More information about the LTA method, identiﬁed subtypes
and their correlates are provided in the Supplementary Materials.
In the current analyses, we included only persons with chronic
depression and a stable depressive subtype over time for the following
reasons. Firstly, stable subtypes are likely more homogeneous. Within
chronic forms of depression some heterogeneity may still exist with
different episodes having a different presentation or etiology,30 but this
can be avoided by including only persons with a stable clinical
presentation. Secondly, by including persons with a chronic depression
(that is, diagnoses present at two different measurements) we capture the
more disabling, severe forms of depression. There is increasing awareness
that single episodes may be distinct from recurrent and chronic forms,
with the latter type being increasingly viewed upon as a chronic recurring
condition characterized by high disability.30,31 These chronic forms
furthermore may have higher heritability than single episodes of
depression.32 Finally, having more homogeneous subtypes may bring us
closer to the underlying etiologies of subtypes.
Severity may also be an important correlate for many biological markers
that makes direct comparison of subtypes of different severity somewhat
difﬁcult. Therefore, we only included the Severe Melancholic and the
Severe Atypical subtypes as they were of similar severity. Furthermore,
melancholic and atypical depression are well recognized in the literature
and are also currently included in DSM-IV. The controls used in the study
were persons without lifetime depressive or anxiety disorders at both the
baseline and 2-year assessment.
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Biological measures
Metabolic syndrome and BMI. Serum levels of triglycerides, high-density
lipid (HDL) cholesterol and fasting plasma glucose were determined in
plasma samples, for which blood samples were collected after an overnight
fast. Blood samples were drawn into vacuum tubes between 0730–0930hrs
and kept frozen at  80 1C. Blood pressure, height, weight and waist
circumference were measured during the medical assessment. Blood
pressure was measured twice during supine rest on the right arm with
the Omron M4-I, HEM 752A (Omron Healthcare Europe B.V., Hoofddorp, The
Netherlands) and was averaged over the two measurements. In the analyses,
positive outliers (mean þ / 3 s.d.) were trimmed to the mean þ / 3 s.d.
(waist circumference n¼ 3, triglycerides n¼ 5, HDL n¼ 5, systolic blood
pressure n¼ 5, diastolic blood pressure n¼ 2, glucose n¼ 5). Metabolic
syndrome was deﬁned according to the Adult Treatment Panel III.33,34 The
criteria are as follows: (1) waist circumference 4102 cm in men or 488 cm
in women, (2) triglycerides X1.7mmol l 1 (150mgdl 1), (3) HDL
cholesterol o1.03mmol l 1 (40mgdl 1) in men or o1.30mmol l 1
(50mgdl 1) in women, (4) blood pressure X130/85mmHg or use of
antihypertensives and (5) fasting glucoseX 6.1mmol l 1 (110mgdl 1) or
drug treatment for elevated glucose. Further, a count of the total number
of positive criteria was constructed. BMI was calculated (kgm 2).
Inﬂammatory markers. CRP and IL-6 were assayed at the Clinical
Chemistry department of the VU University Medical Center. High-sensitivity
plasma levels of CRP were measured in duplicate by an in-house ELISA
based on puriﬁed protein and polyclonal anti-CRP antibodies (Dako,
Glostrup, Denmark). The lower detection limit of CRP is 0.1mg l 1 and the
sensitivity is 0.05mg l 1. Intra- and inter-assay coefﬁcients of variation
were 5% and 10%, respectively. Plasma IL-6 levels were measured in
duplicate by a high-sensitivity enzyme-linked immunosorbent assay
(PeliKine CompactTM ELISA, Sanquin, Amsterdam, the Netherlands).
Comparison of IL-6 levels according to this assay with that of the IL-
6 R&D array (R&D systems Minneapolis, MN, USA) in 77 random NESDA
participants showed a correlation of 0.88, conﬁrming comparability of
these methods. The lower detection limit of IL-6 is 0.35 pgml 1 and the
sensitivity is 0.10 pgml 1. Intra- and inter-assay coefﬁcients of variation
were 8% and 12%, respectively. Plasma TNF-a levels were assayed in
duplicate at Good Biomarker Science, Leiden, the Netherlands, using a
high-sensitivity solid phase ELISA (Quantikine HS Human TNF-a Immu-
noassay, R&D systems, Minneapolis, MN, USA). The lower detection limit of
TNF-a is 0.10 pgml 1 and the sensitivity is 0.11 pgml 1. Intra- and inter-
assay coefﬁcients of variation were 10% and 15%, respectively.
Cortisol. At the baseline interview, participants were instructed to collect
saliva samples at home on a regular day (preferably, a working day). This
method has been shown to be a reliable and minimally intrusive method
to assess the active, unbound form of cortisol.35 Samples for the cortisol
awakening response were obtained using Salivettes (Sarstedt AG and Co,
Nu¨mbrecht, Germany) at awakening (T1), and 30 (T2), 45 (T3) and 60 (T4)
minutes later. Additionally, participants collected a sample at 1100 hrs.
Samples were stored in refrigerators and returned by mail. After receipt,
Salivettes were centrifuged at 2000 g for 10min, aliquoted and stored at
 80 1C. Cortisol analysis was performed by competitive electro-
chemiluminescence immunoassay (E170; Roche, Basel, Switzerland) as
described by van Aken et al.36 The functional detection limit was
0.07mgdl 1 and the intra-assay and inter-assay variability coefﬁcients in
the measuring range were o10%. Values collected outside a margin of
5min before or after the time protocol were recoded as missing. Persons
using corticosteroids or who were pregnant or breastfeeding were
excluded from analyses (n¼ 47). Values that were larger than the
meanþ 2 s.d. were coded as missing (n¼ 24).
For the cortisol awakening response, the area under the curve with
respect to the increase (AUCi) and with respect to the ground (AUCg) were
calculated using trapezoid formulas.37 To calculate AUCi and AUCg,
samples of at least three time points had to be available. For those with
one missing sample (n¼ 26), the missing value was imputed using a linear
regression model, including information on the available three cortisol
levels, age, sex, awakening time and smoking status.38 To assess the
diurnal cortisol slope, we calculated the slope mean decline per hour as:
diurnal slope¼ (Tawakening–Tevening)/(time Tevening—time Tawakening).39
Covariates and descriptive variables
Potential confounding variables that were considered included age, sex,
educational level and smoking (yes/no). Models for cortisol AUCg and AUCi
were additionally corrected for awakening time on the day of saliva
collection.
To describe groups, we used several clinical characteristics, including
severity of depressive symptoms as measured with the Inventory of
Depressive Symptoms 30-item self-report,40 age of onset assessed in the
CIDI interview, duration of symptoms in the 4 years before baseline as
measured with the Lifechart method41 and family history of depression in
ﬁrst-degree relatives (not including offspring) based on self-report.42
Antidepressant use was based on drug-container inspection of all the
drugs used in the past month (on at least 50% of days), classiﬁed according
to the World Health Organization Anatomical Therapeutic Chemical
classiﬁcation, and included selective serotonin reuptake inhibitors (SSRI;
ATC code N06AB), serotonin-norepinephrine reuptake inhibitors (SNRI;
N06AX16, N06AX21), tricyclic antidepressants (TCAs; N06AA) and
tetracyclic antidepressants (TeCAs; N06AX03, N06AX05, N06AX11).
Duration of antidepressant treatment was also assessed in number of
months. Also, use of anti-inﬂammatory medication (M01A, M01B, A07EB,
A07EC), statins (C10AA, C10B) and corticosteroids (H02, R03BA, R03AK,
D07) were assessed. Diagnoses of cardiovascular disease and diabetes
were based on self-report.
Statistical analyses
All analyses were performed in SPSS, version 19. In case of non-normal
distributions, biological measures were log-transformed when necessary.
First, means of metabolic syndrome variables, inﬂammatory markers and
cortisol variables were compared across groups (controls, melancholic
depression, atypical depression) using analyses of variance. In multivariable
analyses we corrected for potential confounders. To test our hypotheses,
we tested differences between atypical and melancholic depression. We
also tested differences between atypical and melancholic depression
versus controls, to evaluate whether they were different from controls (that
is, inﬂammation and metabolic syndrome in atypical depression, and
cortisol in melancholic depression) or similar to controls (that is,
inﬂammation and metabolic syndrome in melancholic depression, and
cortisol in atypical depression). In addition, we calculated effect sizes
(Cohen’s d). For cortisol, we also analyzed the four cortisol awakening
measurements in a linear mixed model, adjusting for age, sex, educational
level, smoking and awakening time. As mixed models can handle missing
data through maximum likelihood estimation, we included all persons who
had at least two cortisol measurements available.
RESULTS
In Table 1, we describe the socio-demographic and clinical
characteristics of the two LCA-based depressive subtypes and
controls. Groups did not differ in age, but the depressed groups
were more often female, had lower educational levels and were
more often smokers. In terms of clinical characteristics, persons
with melancholic depression had a slightly higher severity and
chronicity than persons with atypical depression, but otherwise
the depressed subtypes were comparable. With the exception of
TCAs and TeCAs, used by only nine and seven persons,
respectively, duration of treatment was relatively short. Duration
of TeCAs was longer in atypical depressed persons. There were no
differences in prevalence of diabetes and cardiovascular disease,
statin use and corticosteroid use across groups, but the depressed
groups used anti-inﬂammatory medication more often.
Unadjusted means and s.ds. for metabolic syndrome variables
and BMI, inﬂammatory markers and cortisol are presented in
Table 2. Of the metabolic measures, waist circumference, BMI and
the number of metabolic syndrome criteria were signiﬁcantly
more common in atypical depression compared with controls and
melancholic depression, and the levels of triglycerides were
elevated in the atypical group compared with controls. Systolic
blood pressure was signiﬁcantly elevated in controls compared
with both the depressive groups. CRP, IL-6 and TNF-a levels were
most elevated in atypical depression. Of the cortisol measures,
AUCg was signiﬁcantly higher in melancholic depression com-
pared with controls and atypical depression, while diurnal slope
was lower in atypical depression compared with controls and
melancholic depression.
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Table 1. Group characteristics of depressive subtype groups and controls
N Controls Melancholica Atypicala P-value
N¼ 543 N¼ 111 N¼ 122
Demographics and health indicators
Female (%) 776 60.6 65.8 79.5 o0.0001
Age, mean (s.d.) 776 41.3 (14.6) 40.2 (12.1) 39.6 (12.1) 0.40
Educational level (years), mean (s.d.) 776 12.9 (3.2) 10.8 (3.1) 11.3 (3.3) o0.0001
Smoking (% yes) 776 24.7 59.5 32.8 o0.0001
Clinical characteristics
Severity of depression, mean (s.d.) 233 NA 39.1 (10.0) 35.2 (11.5) 0.01
Age of onset, median (IQR) 233 NA 22.0 (17.0–34.0) 22.0 (16.0–32.0) 0.32
Duration sx(% time), median (IQR) 232 NA 0.40 (0.19–0.66) 0.29 (0.15–0.58) 0.09
Positive family history depression (%) 231 NA 81.7 82.8 0.82
Medication use baseline, N (%)a
SSRI 233 NA 39 (35.1) 39 (32.0) 0.61
SNRI 233 NA 10 (9.0) 10 (8.2) 0.83
TCA 233 NA 4 (3.6) 5 (4.1) 0.85
Tetracyclic antidepressants 233 NA 4 (3.6) 3 (2.5) 0.61
Duration use among users (months), median (IQR)
SSRI 78 NA 6 (3–35) 5 (2–35) 0.66
SNRI 20 NA 5.5 (2.5–24) 4 (2–30) 1.00
TCA 9 NA 20 (3.25–97.5) 36 (3.5–168) 0.73
Tetracyclic antidepressants 7 NA 3 (1.25–4.75) 72 (-b) 0.06
Physical health indicators
Medication use, N (%)
Anti-inflammatory medication 776 8 (1.5) 6 (5.4) 4 (3.3) 0.03
Statins 776 33 (6.1) 5 (4.5) 10 (8.2) 0.50
Corticosteroids 776 24 (4.4) 5 (4.5) 7 (5.7) 0.82
Chronic diseases
DM 776 22 (4.1) 5 (4.5) 8 (6.6) 0.49
CVD 766 20 (3.7) 4 (3.6) 8 (6.6) 0.63
Abbreviations: CVD, cardiovascular disease; DM, diabetes mellitus; IQR, interquartile range; NA, not applicable; SNRI, serotonin-norepinephrine reuptake
inhibitors; SSRI, selective serotonin reuptake inhibitors; sx symptoms; TCA, tricyclic antidepressants.
aSubtypes based on latent class and latent transition analyses.
bIQR not available due to low numbers.
Table 2. Means (s.d.) of biological measures across stable depressive subtypes and controls (N¼ 776)
N Controls Melancholica Atypicala P-value
N¼ 543 N¼ 111 N¼ 122
Metabolic syndrome and BMI
Waist circumference (cm) 774 88.1 (13.5) 86.2 (13.1) 94.0 (15.7) o0.0001 B, C
Triglycerides (mmol l 1) b 764 1.08 (1.67) 1.11 (1.68) 1.22 (1.62) 0.055 B
HDL cholesterol (mmol l 1) 760 1.63 (0.43) 1.59 (0.42) 1.55 (0.42) 0.16
Systolic BP (mmHg) 774 137.5 (19.9) 133.4 (17.3) 132.7 (15.9) 0.012 A, B
Diastolic BP (mmHg) 774 80.9 (11.5) 80.8 (10.3) 81.4 (9.5) 0.91
Fasting plasma glucose (mmol l 1) 766 5.13 (0.78) 5.13 (0.79) 5.21 (0.94) 0.62
No. of MetSyn components, mean (s.d.) 765 1.4 (1.3) 1.4 (1.2) 1.8 (1.4) 0.01 B, C
BMI, mean (s.d.) 776 25.1 (4.6) 24.2 (4.8) 28.7 (6.0) o0.0001 B, C
Inflammatory markers
CRP (mg l 1), mean (s.d.) b 768 1.12 (3.23) 1.18 (3.57) 1.86 (3.48) o0.0001 B, C
IL-6 (pgml 1), mean (s.d.) b 769 0.73 (2.58) 0.75 (2.64) 1.04 (2.42) 0.001 B, C
TNF-a, (pgml 1), mean (s.d.)b 762 0.84 (1.90) 0.78 (1.89) 1.03 (1.97) 0.002 B, C
Cortisol
AUCg 504 18.47 (6.85) 21.82 (8.34) 17.16 (6.13) o0.0001 A, C
AUCi 504 1.62 (6.61) 3.27 (8.74) 2.90 (5.61) 0.10
Diurnal cortisol slope 507 0.75 (0.46) 0.86 (0.51) 0.59 (0.34) 0.001 B, C
Abbreviations: AUCg, area under the curve with respect to the ground; AUCi, area under the curve with respect to the increase; BMI, body mass index; BP,
blood pressure, CRP, C-reactive protein; HDL, high-density lipid; IL-6, interleukin-6; MetSyn, metabolic syndrome; TNF-a, tumor necrosis factor-alpha.
A¼Controls different from Melancholic. B¼Controls different from Atypical. C¼Atypical different from Melancholic.
aSubtypes based on latent class and latent transition analyses.
bTest on log-transformed variable, means are back-transformed.
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After adjustment for age, sex, educational level and smoking, a
similar picture emerged with atypical depression having more
metabolic abnormalities—including now lower HDL cholesterol
also—and higher inﬂammatory markers. Those with atypical
depression were also found to have a higher fasting glucose
compared with controls. Persons with melancholic depression had
a higher AUCg, indicating higher morning saliva cortisol levels
(Table 3). Effect sizes for metabolic components were small, with
the exception of waist circumference and BMI (Table 4). For these
variables, large effect sizes were observed in the range of 0.63–
1.03 for comparisons of atypical versus controls and melancholic.
Small-to-moderate effect sizes were observed for the comparison
of inﬂammatory markers in atypical versus controls (range 0.29–
0.30) and for the comparison of atypical versus melancholic (range
0.39–0.42). For AUCg, effects sizes for the comparison of
melancholic versus control and versus atypical were moderate
with effect sizes of 0.45 and 0.59, respectively. The effect size of
diurnal slope for melancholic versus atypical was of a moderate
size (0.61).
Antidepressant use can affect levels of biological measures.43–45
Although antidepressant use was similar across the two depressed
groups, the comparisons with controls could be affected and
therefore we ran additional analyses adjusting for SSRI, SNRI, TCA
and TeCA. Results showed that patterns remained largely similar,
although effect sizes were somewhat smaller. We also evaluated
the possible inﬂuence of differences in duration of treatment and
long-term treatment by excluding persons using TCAs and TeCAs
(n¼ 16). Exclusion of these persons did not alter the results (data
not shown).
To evaluate the role of BMI, we ran multivariable models with
adjustment for BMI and found that between-group differences
were no longer signiﬁcant for CRP (overall P¼ 0.99) and IL-6
(overall P¼ 0.37; not tabulated). However, persons with atypical
depression still had signiﬁcantly higher TNF-a levels than controls
(P¼ 0.02) and persons with melancholic depression (P¼ 0.01) after
additional correction for BMI (not tabulated).
In an adjusted, linear mixed model analysis using the awaken-
ing cortisol measurements separately, persons with melancholic
depression had a distinct higher morning awakening curve than
persons with atypical depression and controls (Figure 1).
DISCUSSION
This study demonstrated distinct biological correlates of chronic
forms of atypical and melancholic LCA-based subtypes of MDD.
Results from this study conﬁrm our hypotheses that HPA-axis
hyperactivity was a distinct feature of persons with melancholic
depression, whereas atypical depression was characterized by
greater inﬂammation and metabolic abnormalities. These ﬁndings
provide strong evidence that depressive subtypes based on data-
driven techniques do not merely differ in symptom presentation
but also have distinct biological characteristics that distinguish
them from the other subtypes and from the non-depressed
groups. This supports the notion that melancholic and atypical
depressive subtypes may have different etiological pathways and/
or consequences.
Our ﬁnding of hyperactivity of the HPA axis, as indicated by
higher cortisol levels, in melancholic depression conﬁrms the
results of a recent meta-analysis ﬁnding that HPA hyperactivity
was linked with melancholic features of depression.1,13 However,
the effect size of d¼ 0.59 in our study for the comparison of AUCg
values in the melancholic versus atypical groups was larger than
those reported by Stetler and Miller1 for comparison of atypical
versus non-atypical and melancholic versus non-melancholic
Table 3. Adjusted means (s.e.) of biological measures across depressive subtypes and controls (N¼ 776)











Waist circumference (cm) 87.9 (0.5) 85.5 (1.2) 95.5 (1.1) o0.0001 0.07 o0.0001 o0.0001
Triglycerides (mmol l 1) b 1.08 (1.02) 1.06 (1.05) 1.26 (1.04) 0.005 0.70 0.002 0.007
HDL cholesterol
(mmol l 1)
1.63 (0.02) 1.63 (0.04) 1.52 (0.04) 0.022 0.96 0.007 0.04
Systolic BP (mmHg) 137.1 (0.7) 133.2 (1.6) 134.6 (1.5) 0.05 0.03 0.14 0.50
Diastolic BP (mmHg) 80.8 (0.4) 80.7 (1.0) 82.0 (0.9) 0.42 0.93 0.21 0.29
Fasting plasma glucose
(mmol l 1)
5.11 (0.03) 5.13 (0.07) 5.27 (0.07) 0.09 0.83 0.03 0.13
No. of MetSyn
components
1.4 (0.0) 1.3 (0.1) 1.8 (0.1) o0.0001 0.11 0.001 o0.0001
BMI 25.1 (0.2) 23.9 (0.5) 28.8 (0.4) o0.0001 0.02 o0.0001 o0.0001
Inflammatory markers
CRP (mg l 1)b 1.18 (1.05) 1.05 (1.12) 1.67 (1.11) 0.005 0.37 0.004 0.003
IL-6 (pgml 1)b 0.75 (1.04) 0.69 (1.09) 1.00 (1.09) 0.003 0.35 0.003 0.002
TNF-a, (pgml 1)b 0.84 (1.03) 0.77 (1.07) 1.02 (1.06) 0.003 0.23 0.004 0.001
Cortisol
AUCgc 18.44 (0.36) 21.57 (0.92) 17.47 (0.79) 0.002 0.002 0.27 0.001
AUCic 1.73 (0.35) 2.80 (0.90) 2.73 (0.77) 0.34 0.27 0.24 0.95
Diurnal cortisol slope 0.74 (0.02) 0.90 (0.06) 0.62 (0.05) 0.001 0.01 0.04 o0.0001
Abbreviations: AUCg, area under the curve with respect to the ground; AUCi, area under the curve with respect to the increase; BMI body mass index;
BP, blood pressure; CRP, C-reactive protein; HDL, high-density lipid; IL-6, interleukin-6; MetSyn, metabolic syndrome; TNF-a, tumor necrosis factor-alpha.
Adjusted for sex, age, educational level and smoking.
aSubtypes based on latent class and latent transition analyses.
bTest on log-transformed variable, means are back-transformed.
cAdditionally corrected for awakening time.
Differential pathophysiology in depressive subtypes
F Lamers et al
696
Molecular Psychiatry (2013), 692 – 699 & 2013 Macmillan Publishers Limited
depression (d¼  0.34 and d¼ 0.22, respectively). The lower
cortisol and the lower diurnal cortisol slope in atypical depression
compared with melancholic depression conﬁrms that atypical
depression is a distinct phenomenon, as suggested before.1
Although persons with atypical depression did not have different
AUCg and AUCi than controls, they had lower cortisol levels at
awakening and a smaller diurnal slope.
Atypical depression was characterized by both metabolic
disturbances and inﬂammation. Metabolic disturbances
observed in atypical depression included higher BMI, waist
circumference, triglycerides and lower HDL. Elevated levels of
CRP, IL-6 and TNF-a were observed in atypical depression
compared with both melancholic depression cases and controls.
This is contradicting a recent ﬁnding of Yoon et al.,14 who found
no differences in IL-6 and TNF-a but observed increased IL-2 and
decreased IL-4 levels in persons with atypical depression versus
non-atypical depression. A recent study by Karlovic et al.,15
including 32 persons with melancholic depression and 23
persons with atypical depression, also did not ﬁnd differences
between groups for CRP, TNF-a and IL-6 but did ﬁnd higher CRP
in atypical depression compared with controls. Explanations for
the differences in ﬁndings may be the use of a different
deﬁnition (based on LCA) in our study, smaller samples, use of
clinical samples and poorer comparability of subtypes in terms of
severity. As expected, we did not observe differences in
inﬂammatory markers between the melancholic depression
and the control group, suggesting that inﬂammation is limited
to atypical depression. Although elevations in cytokine levels is
said to unequivocally occur in melancholic depression as well,
this could be an effect of severity. Many studies on melancholic
depression include inpatients, but these persons usually have
more severe depression (that is, higher severity, more
comorbidity, more disability). In NESDA, the sample comprised
of persons from the community, as well as from primary and
secondary care, thus giving a fair representative of depressed
persons in the community, as opposed to inpatient samples who
are more likely to consist of only severe cases. Contrary to our
expectations, persons with melancholic depression had lower
systolic blood pressure and lower BMI than controls. Possible
explanations for lower blood pressure include higher use of
antihypertensive drugs and more heart failure among depressed
persons, chronic low blood pressure may be a causal factor for
depression and, lastly, depression and low blood pressure may
have a common underlying factor.46 Effects of nicotine on
appetite may explain the lower BMI in the melancholic group,47
as this group has the highest percentage of smokers.
The association between depression and obesity has also been
widely reported with some evidence for a reciprocal link between
depression and obesity.5 As suggested previously,29,48 the current
results imply that atypical depression underlies the association
between depression with obesity. Higher waist circumference can
be caused by abdominal fat storage in the form of white adipose
tissue, whose main function is the storage of triglycerides.49
Together with the unfavorable lipid proﬁles, these results suggest
that the metabolic dysregulations observed in atypical depression
mainly involve the lipid/fat metabolism. The co-occurrence of
metabolic disturbances and inﬂammation in atypical depression is
not surprising, given that low-grade chronic inﬂammation is linked
to obesity and the metabolic syndrome.50–52 Inﬂammatory markers,
including cytokines, are involved in many physiological domains
that are relevant in depression, including neurotransmitter meta-
bolism, and are known to induce sickness behavior, including
depressive symptoms and symptoms of fatigue.50,51,53 Further-
more, inﬂammation is now increasingly thought to have an
important role in the development of depression54 in what is
called the ‘cytokine hypothesis’ of depression. Because adipose
tissue produces cytokines, including IL-6 and TNF- a,52 the state of
inﬂammation in atypical depression is likely caused by the higher
BMI in this subgroup. Additional models conﬁrmed this, although
the association between atypical depression and TNF-a was
independent of BMI. This ﬁnding is in line with a smaller study of
adults with clinical depression that found that BMI was partially,
but not completely, responsible for increased inﬂammation.55
Notably, a small study of depressed persons (of whom subtype
was not mentioned) and BMI-matched controls found morning
elevations of IL-6 in cases but no differences in morning cortisol.4
Table 4. Effect sizes (95% CI)
Cohen’s d (95% CI)
Melancholic versus control Atypical versus control Atypical versus melancholic
Metabolic syndrome components
Waist circumference (cm)  0.20 ( 0.40 to 0.01) 0.63 (0.43 to 0.83) 0.82 (0.55 to 1.09)
Triglycerides (mmol l 1)a  0.04 ( 0.25 to 0.16) 0.31 (0.11 to 0.51) 0.35 (0.09 to 0.61)
HDL cholesterol (mmol l 1) 0.00 ( 0.21 to 0.21)  0.28 ( 0.48 to  0.08)  0.28 ( 0.54 to  0.02)
Systolic BP (mmHg)  0.24 ( 0.44 to  0.04)  0.15 ( 0.35 to 0.04) 0.09 ( 0.17 to 0.34)
Diastolic BP (mmHg)  0.01 ( 0.22 to 0.19) 0.13 ( 0.07 to 0.33) 0.14 ( 0.12 to 0.40)
Fasting plasma glucose (mmol l 1) 0.03 ( 0.18 to 0.23) 0.23 (0.03 to 0.42) 0.20 ( 0.06 to 0.45)
No. of MetSyn components  0.17 ( 0.38 to 0.03) 0.36 (0.16 to 0.55) 0.52 (0.26 to 0.78)
BMI  0.25 ( 0.46 to  0.05) 0.78 (0.58 to 0.98) 1.03 (0.75 to 1.30)
Inflammatory markers
CRP (mg l 1)a  0.10 ( 0.30 to 0.11) 0.29 (0.09 to 0.49) 0.39 (0.12 to 0.65)
IL-6 (pgml 1)a  0.10 ( 0.31 to 0.10) 0.30 (0.10 to 0.50) 0.40 (0.14 to 0.66)
TNFa (pgml 1)a  0.13 ( 0.34 to 0.07) 0.30 (0.10 to 0.50) 0.42 (0.16 to 0.68)
Cortisol
AUCg 0.45 (0.17 to 0.73)  0.14 ( 0.39 to 0.10)  0.59 ( 0.93 to  0.24)
AUCi 0.16 ( 0.12 to 0.44) 0.15 ( 0.10 to 0.39)  0.01 ( 0.35 to 0.33)
Diurnal cortisol slope 0.34 (0.07 to 0.61)  0.26 ( 0.50 to  0.02)  0.61 ( 0.94 to  0.26)
Abbreviations: AUCg, area under the curve with respect to the ground; AUCi, area under the curve with respect to the increase; BP, blood pressure; BMI, body
mass index; CI, confidence interval; CRP, C-reactive protein; HDL, high-density lipid; IL-6 interleukin-6; MetSyn, metabolic syndrome; TNF-a, tumor necrotic
factor-alpha. Melancholic and atypical subtypes based on latent class and latent transition analyses.
aLog-transformed variable.
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Although the found associations could indicate pathophysiolo-
gical pathways, they could also represent epiphenomena.
Although evidence for both pathophysiology and epiphenomena
has been found for inﬂammation,3 a larger body of evidence
seems to indicate inﬂammation as a pathophysiological
process.3,51,56–60 For cortisol, evidence also points towards a
pathophysiological process.61 The current ﬁndings have important
implications for future studies on pathophysiological mechanisms.
Taking into account depressive subtypes in studies using newer
biomarker techniques, such as cytokine microarrays and
biomarkers pathway analyses, could bring us forward in the
search for new biomarkers and treatments of depression. These
results also suggest that stratiﬁcation of analyses of new
treatments by subtype may be informative in future studies.
In this study, we focused on HPA axis and inﬂammatory makers,
but other biological systems may be helpful in distinguishing
melancholic and atypical depressive subtypes. For instance, sleep-
electroencephalogram studies have provided evidence for altered
sleep in melancholic depression such as low slow-wave activity,
short rapid eye movement latency and high rapid eye movement
density, whereas in atypical depression, such alterations have not
been reported.62–64
Several limitations should be considered when interpreting the
results of this study. First, the cross-sectional character of this
study does not allow for making causal inferences. Second, the
study sample did not include inpatients. Third, it should be noted
that the subtypes used were not based on DSM-IV criteria, but on
more LCA/LTA classiﬁcation methods. However, as especially the
criteria for atypical depression have been criticized,26,27,65 having
subtypes based on more empirically based classiﬁcation methods
may be preferable. Fourth, we only included chronically depressed
persons and therefore we can only generalize to chronic cases of
depression.
To conclude, these ﬁndings provide evidence for heterogeneity
of MDD based on pathophysiological measures; chronic forms of
LCA-derived subtypes of melancholic and atypical depression
have distinct biological correlates that may inform the etiology
and treatment strategies for depression. Although hyperactivity of
the HPA axis characterized melancholic depression, atypical
depression is characterized by inﬂammation and metabolic
abnormalities. These distinct pathophysiological indicators across
depressive subtypes should aid future research on pathophysio-
logical pathways and treatment of depression.
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Figure 1. Cortisol morning awakening curve across depressive
subtypes and controls. Mean salivary cortisol levels from a linear
mixed model, adjusted for age, sex, educational level, smoking,
body mass index and awakening time. Melancholic and atypical
subtypes based on latent class and latent transition analyses: (a)
mean cortisol of Severe Atypical (Sev Atyp) significantly lower than
Severe Melancholic (Sev Mel) and controls (Po0.05); (b) mean
cortisol of Severe Melancholic significantly higher than Severe
Atypical and controls (Po0.05); and (c) mean cortisol of Severe
Melancholic significantly higher than controls (Po0.05). Main effects
of mixed model are as follows: For persons with Severe Melancholic
versus Severe Atypical, P¼ 0.001, interaction with time P¼ 0.45. For
persons with Severe Melancholic versus Controls P¼ 0.12, interac-
tion with time P¼ 0.13. For persons with Severe Atypical versus
Controls P¼ 0.008, interaction with time P¼ 0.006.
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